ERBB2 and cancer: Invasive cancers with more aggressive characteristics showed significantly shorter BAT compared with those with less aggressive characteristics: tumor grade 3 vs. tumor grades 1–2, IDC vs. ILC, and triple negative or HER2 type vs. luminal type.